French
A French version of the website is coming soon!

A journey towards hope

for ALS patients

"Five in Five" 5 ALS compounds with PoC data in 5 years.

Our mission is to deliver an effective ALS treatment to patients around the world using an innovative clinical platform trial design that gives us "7+ shots on goal" maximizing the chance of identifying a disease modifying treatment while being highly capital efficient.

Learn more

What we are?

Mission driven

For all types of ALS

Collaborative

Supported by Advisors in the ALS Community

relationship-1relationship-2relationship-3relationship-5

Our team

Raya Therapeutic is a clinical-stage company with a plan to deliver an effective ALS treatment to patients around the world.
Headed by the founder and President, Anjan Aralihalli, Raya’s leadership team includes experts who have substantial know-how and connections in the ALS field including ALS clinicians, consortiums, researchers and patient advocacy groups. Raya will use an innovative clinical platform trial design which will become the new standard for addressing multifactorial diseases, such as ALS, with combination therapies.

Anjan Aralihalli

Anjan Aralihalli

President & Founder

Dr. Angela Genge

Dr. Angela Genge

Clinical Advisor

Kim Staats (PhD)

Kim Staats (PhD)

Scientific Advisor

Micheline Beauvais

Micheline Beauvais

Finance

Raya's unique approach

Raya has a unique portfolio of 5 new chemical entities with demonstrated potential in ALS and robust in-human data

Learn more

Raya’s ALS Development Plan

Innovative clinical trial design that gives Raya
“7+ shots on goal” for an ALS approval, maximizing the probability of approval, while at the same time, being highly capital efficient

Learn more

Latest News

Raya Therapeutic announces early-stage R&D collaboration with argenx
Raya Therapeutic announces early-stage R&D collaboration with argenx
July 12, 2023

Raya Therapeutic Inc., (“Raya”) a mission-driven company focused on the treatment of neurodegenerative diseases, has entered into an early-stage R&D collaboration with argenx.

CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University
CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University
June 20, 2021

CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University to develop new treatments for Amyotrophic Lateral Sclerosis (ALS).

The ALS Association Awards $1.6 Million to Expand the Drug Development Pipeline
The ALS Association Awards $1.6 Million to Expand the Drug Development Pipeline
February 27, 2023

The ALS Association has awarded $1.6 million to fund four promising preclinical research projects through its Lawrence and Isabel Barnett Drug Development Program.

Development of cell based assays
Development of cell based assays
March 18, 2022

Therapeutic development for ALS has been challenging for many reasons, including the extreme variability in patient presentation, but also due to the many biological pathways that are affected and contribute to motor neuron degeneration.


© Copyright 2023 Raya Therapeutic - All Rights Reserved.

Email

admin@rayatherapeutic.com